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Abstract
Background: In order to investigate host factors associated with the establishment of persistent foot-and-mouth
disease virus (FMDV) infection, the systemic response to vaccination and challenge was studied in 47 steers.
Eighteen steers that had received a recombinant FMDV A vaccine 2 weeks earlier and 29 non-vaccinated steers
were challenged by intra-nasopharyngeal deposition of FMDV A24. For up to 35 days after challenge, host factors
including complete blood counts with T lymphocyte subsets, type I/III interferon (IFN) activity, neutralizing and
total FMDV-specific antibody titers in serum, as well as antibody-secreting cells (in 6 non-vaccinated animals)
were characterized in the context of viral infection dynamics.
Results: Vaccination generally induced a strong antibody response. There was a transient peak of FMDV-specific
serum IgM in non-vaccinated animals after challenge, while IgM levels in vaccinated animals did not increase
further. Both groups had a lasting increase of specific IgG and neutralizing antibody after challenge.
Substantial systemic IFN activity in non-vaccinated animals coincided with viremia, and no IFN or viremia was
detected in vaccinated animals. After challenge, circulating lymphocytes decreased in non-vaccinated animals,
coincident with viremia, IFN activity, and clinical disease, whereas lymphocyte and monocyte counts in vaccinated
animals were unaffected by vaccination but transiently increased after challenge. The CD4+/CD8+ T cell ratio
in non-vaccinated animals increased during acute infection, driven by an absolute decrease of CD8+ cells.
Conclusions: The incidence of FMDV persistence was 61.5 % in non-vaccinated and 54.5 % in vaccinated
animals. Overall, the systemic factors examined were not associated with the FMDV carrier/non-carrier
divergence; however, significant differences were identified between responses of non-vaccinated and
vaccinated cattle.
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Background
Foot-and-mouth disease virus (FMDV; family Picorna-
viridae; genus Aphthovirus) causes a highly contagious,
acute disease of cloven-hoofed animals, with fever, lame-
ness, and vesicular lesions of the feet, tongue, muzzle,
and teats reviewed in [1–3]. Foot-and-mouth disease
(FMD) is a difficult and expensive disease to control and
eradicate due to its wide host range, low minimum infec-
tious dose, rapid rate of replication, high level of viral
shedding, and multiple modes of transmission [1, 3]. The
situation is further complicated by an important subclin-
ical divergence that occurs after acute infection of rumi-
nants: some animals remain subclinically infected for
up to 3 years (“FMDV carriers”) ([2], reviewed in [4, 5]),
while others completely clear the virus within 1 to 2 weeks
(“non-carriers”). The definition of an FMDV carrier estab-
lished by the World Organisation for Animal Health
(OIE) is an animal from which infectious FMDV can be
recovered at greater than 28 days after infection [6].
The bovine nasopharynx [7–12] and regional lymph
nodes [13] have been identified as sites of this persist-
ence, but it is poorly understood how FMDV evades
clearance by the host immune response at these sites
[14]. It is also unknown whether there are pre-existent
factors or patterns in the virus-host interaction during
and after acute infection that can be used to predict or
influence the ultimate outcome of virus clearance ver-
sus persistence.
Type I and type III interferons (IFN) are important
parts of the early innate immune response to viral in-
fection and are often crucial in controlling or eliminat-
ing infection (reviewed in [15]). All cells in the body
are responsive to type I IFNs, whereas the type III IFN
receptor is mostly restricted to gastrointestinal and air-
way epithelia [16]. Several reports have demonstrated
strong IFN activity during FMDV infection in cattle
using an Mx/CAT reporter system which does not dif-
ferentiate between IFN type I and type III [17–22].
Using this method, type I/III IFN activity has been
found in circulating plasmacytoid dendritic cells (pDCs)
[18, 23] and in tissues at sites of virus replication [22].
However, it is unclear how much of the systemically de-
tected IFN originates within the vasculature as opposed
to from sites of infection in tissues.
In pigs, FMDV infection leads to lymphopenia and
immune suppression, manifested as a significant loss of
circulating T cells [24, 25]. Significant lymphopenia dur-
ing acute FMDV infection of cattle has been described
[20, 26], but other studies have reported that no changes
occur in total circulating leukocytes or relative lympho-
cyte subpopulations [27, 28]. One report concluded that
the T-cell response to mitogen and non-FMDV antigens
was not impaired during acute FMDV infection, but no
FMDV-specific T-cell responses were detected [28].
In earlier experiments, the depletion of CD4+ cells
in vivo significantly reduced neutralizing antibody titers
and delayed class switching in cattle vaccinated with
inactivated FMDV [29]. However, in non-vaccinated
cattle, CD4+ depletion before FMDV infection had no
effect on clinical signs, the induction of neutralizing
antibodies, or the acute clearance of virus from the cir-
culation [27]. These and other studies have concluded
that the antigenic structure of the FMDV capsid, the
high local antigen concentration, and the strong cyto-
kine response during acute infection likely are key factors
in the efficient induction of T cell-independent antibody
responses [29, 30].
CD8+ cytotoxic T lymphocytes (CTLs) from vaccinated
pigs are capable of selectively killing FMDV-infected cells
in vitro [31], and infection of pigs with FMDV also leads
to a clear CTL response [32]. However, in cattle, partial
depletion of CD8+ cells did not affect the resolution of
acute FMDV infection [27]. Given that the acute phase
of an FMDV infection is concluded before a significant
adaptive CTL response can be mounted [28], it is likely
that the control of the infection is mediated by a T-cell-
independent neutralizing antibody response and type I/
III interferon signaling. Overall, the role of bovine
antigen-specific T cells in FMDV infection remains
unresolved, and it is unclear how FMDV evades the
CTL response during persistent infection.
The kinetics of circulating FMDV-specific antibody-
secreting cells in the context of antibody levels and
neutralizing activity have not yet been examined. FMDV in-
fection generally elicits a rapid, strong, and lasting antibody
response. Coincident with the first detection of antibody
there is a rapid clearance of virus from the circulation and
a more gradual reduction of virus shedding. Although cir-
culating antibodies are generally believed to be the primary
mediators of immunity after infection or vaccination [3], it
is well known that vaccines prevent viremia and generalized
disease, but not primary local infection, e.g., in the pharynx.
Several studies have reported shedding of infectious FMDV
in nasal, oral, or oropharyngeal fluids of vaccinated animals
following virus exposure [10, 33–37], which is consistent
with primary infection of the upper respiratory or gastro-
intestinal tracts. Virus replication in the nasopharyngeal
mucosa of vaccinated animals in the present study has
been demonstrated in a separate publication [38]. The
occurrence of persistent, asymptomatic FMDV infec-
tion in vaccinated cattle [9, 10, 34, 36, 37, 39, 40] pro-
vides further unequivocal evidence that vaccination
does not prevent primary infection.
Similarly, antibodies are ineffective in clearing virus
from the pharynx of carrier ruminants [4], and substantial
antibody levels – in serum as well as in secretions-have
been reported in animals that remained persistently in-
fected with FMDV [21, 41–43]. In vaccinated animals,
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protection against challenge is correlated with neutralizing
antibody in circulation, but low antibody levels can also be
protective [35, 44, 45] and animals with high neutralizing
titers can develop disease after challenge [37].
The overarching goal of the present study was to eluci-
date systemic host factors associated with the response
to FMDV in cattle during early and late stages of infec-
tion and to categorize these responses in the context of
vaccination status and carrier-state divergence. For this
purpose, serological and hematological parameters as
well as lymphocyte sub-populations were investigated
in vaccinated and non-vaccinated cattle from the day of
FMDV vaccination and/or infection to the persistent/
recovered phase. Trends associated with acute disease,
vaccination, and the development of the FMDV-carrier
state were examined in the context of clinical, virological,
and serological data collected from the same animals.
Methods
Animals
Forty-seven Holstein steers (6 to 8 months, ~200 kg)
were obtained from an experimental livestock provider
(Thomas D. Morris Inc., Reisterstown, MD, USA) accre-
dited by the Association for Assessment and Accreditation
of Laboratory Animal Care International and registered
with the United States Department of Agriculture (USDA).
The animals were housed together in a BSL-3-Ag animal
facility from the time of arrival until euthanasia, and were
given an acclimation period of 2 weeks before the start
of the experiment. The health status of all animals was
assessed daily throughout the study period. Based on
daily clinical assessments, analgesics and anti-inflammatory
drugs (flunixin meglumine, 1.1–2.2 mg/kg; butorphanol
tartrate, 0.1 mg/kg) were administered to mitigate pain
associated with severe clinical FMD as needed. Steers
were sedated with xylazine (intramuscular, 0.22 mg/kg)
for inoculations and clinical exams; after the procedure,
the sedation was reversed with tolazoline (intravenous,
2 mg/kg).
Vaccination
Two weeks before infection, eighteen of the 47 steers
were immunized using a recently licensed recombinant
FMD serotype A vaccine (USDA product code 1FM.1R0;
manufactured by Antelope Valley Bios, Lincoln, NE, USA).
This vaccine contains the P1-2A and 3Cpro coding re-
gions from FMDV A24 Cruzeiro within a replication-
deficient human adenovirus serotype 5 vector [46]. The
steers were intramuscularly injected with the product
release dose in a 2 mL total volume containing com-
mercially available adjuvant (product #7010101, VaxLiant,
Lincoln, NE, USA).
Challenge infection
All animals were clinically evaluated and sampled prior
to inoculation, to ensure their FMDV-free status and
the absence of elevated systemic type I/III IFN levels
that could interfere with initial FMDV replication. On
day 0 of the experiment, all animals were inoculated
with 105 infectious doses (titrated in bovine tongue epithe-
lium) [6] of FMDVA24 Cruzeiro [47] in 2 mL of minimum
essential medium (MEM) with 25 mM HEPES by intrana-
sopharyngeal (INP) deposition [38, 48]. The successful
deposition of virus was confirmed in all animals by col-
lection of nasal and oral fluids after removal of the in-
oculation catheter (data not shown).
Clinical evaluation
From the day of challenge until 10 days post inoculation
(dpi), clinical scores were recorded on a scale from 0 to
5 accounting for presence of FMD vesicles on each foot
or anywhere on the head (oral cavity or nasal epithelia)
[12]. Clinical examinations with sedation were performed
daily in non-vaccinated animals and every other day in
vaccinated animals, either throughout the first 10 dpi, or
until the animal had reached full clinical score. Rectal
body temperatures were taken every day for the entire
duration of the experiment.
Euthanasia and tissue collection
A subset of study animals were euthanized at predeter-
mined time points during acute and post-acute phases
of infection (0 to 14 dpi) for detailed tissue-based patho-
genesis studies which have been presented in separate
publications [12, 38]. All samples and data collected be-
fore necropsy, however, are included herein. Specifically,
four non-vaccinated animals were euthanized on 1 dpi,
and two each on 2, 3, 4, 7, 10, and 14 dpi. Among vacci-
nated animals, two animals were euthanized on each of
1, 2, and 3 dpi, and one on 14 dpi (see Fig. 1). Sodium
pentobarbital (intravenous, 86 mg/kg) was used for all
euthanasias.
The OIE defines FMDV carriers as animals in which
the virus persists for more than 28 days after infection
[6]. For the animals in this study, however, it was found
that the persistence status could be reliably determined
by 21 dpi (see Results section for details).
Since the FMDV carrier status was not determined for
animals euthanized earlier than 21 dpi, these animals were
excluded from graphical and statistical analyses that dis-
criminated animals by persistence status; however, these
animals were included in all analyses that did not require
their persistence status to be defined. Twenty-four out of
47 animals (13 non-vaccinated and 11 vaccinated) were
kept alive beyond 21 dpi, which was determined to be the
threshold at which it was possible to consistently conclude
from oropharyngeal fluid samples whether an animal had
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cleared the infection or entered the FMDV carrier state.
With the exception of three vaccinated animals in which
infection could not be confirmed (see Results section for
details), all animals that were kept alive to 21 dpi or longer
were included in all analyses.
Blood and probang samples
Blood was collected from the jugular vein on the day of
vaccination (immediately before), on days 4 and 7 post-
vaccination (dpv), on the day of challenge (immediately
before), then daily for the first ten dpi and afterwards
weekly until 35 dpi. Samples were collected in BD Vacu-
tainer® tubes containing either K2EDTA for hematology,
heparin for PBMC separation, or serum-separator gel.
Starting on 7 dpi (21 dpv) in vaccinated animals and 14
dpi in non-vaccinated animals, oropharyngeal fluids (OPF)
were collected by probang cup [49] two times per week.
Probang cup contents were mixed with an equal volume
of cold MEM with 25 mM HEPES immediately after
collection and then kept on ice. Upon arrival in the
laboratory, serum tubes were centrifuged for harvesting
(10 min at 1000 × g and 4 °C), and OPF samples were
immediately processed as described previously [10],
including treatment with 1,1,2-trichlorofluoroethane
(TTE) to reactivate antibody-bound virus [50].
The PBMC preparation, surface marker staining, and
flow cytometric data collection have been described previ-
ously [51]. Briefly, for separation of PBMCs, 18 mL of fresh
heparinized blood were diluted in Dulbecco’s phosphate-
buffered saline (PBS; Life Technologies, Carlsbad, CA,
USA), underlaid with Histopaque® 1083 (Sigma-Aldrich, St.
Louis, MO, USA), and centrifuged. Harvested PBMCs were
washed twice with PBS, counted, and resuspended at a
concentration of 107 cells/mL in either fetal bovine serum
(FBS; GE Healthcare Life Sciences, Logan, UT, USA)
with 10 % (v/v) dimethyl sulfoxide (Sigma-Aldrich) for
freezing (for flow cytometry) or in ELISPOT media (RPMI-
1640 with antibiotics, 0.1 mM non-essential amino acids,
2 mM L-glutamine, 10 mM HEPES, 1 mM sodium pyru-
vate [all Life Technologies], and 10 % FBS) for immediate
use. Frozen cells were stored at −70 °C for no longer than
thirty days before flow cytometry analysis.
FMDV RNA detection and virus isolation
Real-time RT-PCR and virus isolation for FMDV detection
in serum and OPF were performed as previously described
Fig. 1 Overview of the experimental timeline. Each bar represents one animal, with the length of the bar corresponding to the time the animal
remained in the experiment after challenge infection (21 dpi, the revised cut-off by which FMDV persistence status could be determined, is
marked by a vertical line). Non-vaccinated animals are shown in red, vaccinated animals in blue. Solid-colored bars are FMDV carriers, unfilled bars
are non-carriers. Striped bars are used when the persistence status of an animal could not be determined because it was euthanized before 21 dpi.
Asterisks mark the three animals without convincing evidence of infection (see Results section for details)
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[52]. Briefly, FMDV viral RNA was quantified by real-time
RT-PCR targeting the 3D region of the FMDV genome [53]
with forward and reverse primers adapted from Rasmussen
et al. [54]. Samples with cycle threshold (Ct) values lower
than 45 were considered positive. Serial 10-fold dilutions of
in vitro synthesized FMDV RNA of known concentration
were used to convert Ct values to FMDV RNA genome
copy numbers (GCN) per mL of sample. After the conver-
sion, the cut-off Ct value corresponded to a detection limit
of 1.57 log10 FMDV GCN/mL.
Type I/III IFN bioassay
Type I/III IFN activity in serum was quantified using
the Mx/CAT reporter assay as previously described
[22]. Briefly, serum samples collected during the first
10 days after challenge were incubated for 24 h with
recombinant Madin-Darby bovine kidney cells that ex-
press chloramphenicol acetyltransferase (CAT) under
the control of an Mx1 promoter [17]. CAT expression
in the cells was measured with a commercially available
ELISA kit (Roche Diagnostics, Indianapolis, IN, USA),
and IFN levels in unknown samples were derived from
a standard curve of serial dilutions of recombinant hu-
man interferon-α 2a with known potency (PBL Assay
Science, Piscataway, NJ, USA) that was run in parallel.
Results are reported as international units (IU) of IFN
per mL of serum. The Mx/CAT assay does not distin-
guish between type I and type III interferon [20].
Hematology
For each whole blood sample from all animals, a complete
blood count (CBC) was performed on the same day
with a Hemavet 950FS veterinary hematology system
(Drew Scientific, Waterbury, CT, USA), following the
manufacturer’s instructions. High and low values were
flagged by the analyzer based on factory-set normal
limits. Among the blood parameters reported by the
analyzer, only the total white blood cell (WBC) count and
its principal components are reported here (in 1000 s [K]
of cells per μL of blood). The WBC count is the sum of
five subpopulations, with neutrophils, lymphocytes, and
monocytes together comprising over 90 % of all circulat-
ing white blood cells [55]. The bovine reference ranges are
600 to 4000 neutrophils, 2500 to 7500 lymphocytes, and 0
to 900 monocytes per μL of blood [56].
Flow cytometry
PBMCs from all animals were evaluated by flow cytom-
etry. Cells were thawed in a water bath at 37 °C, slowly
diluted in warm RPMI-1640 media with 10 % FBS, and
washed twice with PBS [57]. All samples were stained
in duplicate; first with an amine-reactive dye (LIVE/
DEAD® Fixable Yellow; Life Technologies), then with
monoclonal antibodies against bovine CD3 (MM1A,
IgG1, Washington State University, Pullman, WA, USA),
the δ chain of the γδ T cell receptor (GB21A, IgG2b,
Washington State University), CD4 (CC8, IgG2a, conju-
gated with FITC, Bio-Rad, Hercules, CA, USA), and CD8
(CC63, IgG2a, Alexa Fluor® 647, Bio-Rad), and finally
with polyclonal goat antibodies against murine IgG1
(allophycocyanin-cyanine7; SouthernBiotech, Birmingham,
AL, USA) and IgG2b (R-phycoerythrin; SouthernBiotech).
Compensation controls and fluorescence-minus-one con-
trols were included for each antibody/dye combination.
After each staining step, cells were washed twice in cold
FACS buffer (PBS with 0.3 % [v/v] bovine serum al-
bumin fraction V [Life Technologies] and 0.1 % [w/v]
sodium azide).
Stained cells were analyzed in a three-laser LSR II flow
cytometer (BD). Initially, events were gated based on
forward and side scatter, equal pulse height/area ratio
(for single-cell selection), as well as live/dead staining
behavior, with low dye uptake considered indicative of
membrane integrity and cell viability [58]. The bound-
aries of a morphological lymphocyte gate (defined by
forward and side scatter) were established by backgating
from CD3. Among all live cells in that gate, T lymphocytes
were then identified by CD3+ staining. At least 10000
CD3+ cells were evaluated per sample. CD3+ γδTCR−cells
were presumed to be αβ T lymphocytes, and were exam-
ined for CD4 and CD8 expression. All surface marker gat-
ing was done automatically with “snap to” interval gates in
single-parameter histograms in BD FACSDiva 8.
The flow cytometer only measures the relative quan-
tities (percent abundance) of T lymphocyte subsets but
does not provide absolute cell counts. Because percent
abundance can be misleading when assessing the change
in a population of cells over different experimental con-
ditions [59], the flow cytometry and hematology data
were combined [60] to obtain absolute counts of the
CD4+ and CD8+ αβ T lymphocyte subpopulations. The
absolute number of cells in each subpopulation was cal-
culated based on the complete blood count obtained
with the Hemavet analyzer as described by Riondato
et al. [61]. Briefly, the total lymphocyte counts per mL
of peripheral blood were assigned to the morphological
lymphocyte gate on the flow cytometer. Absolute num-
bers for the subpopulations were then obtained by seri-
ally applying the percentage-of-parent values to this
total count, beginning with the CD3 gate. Absolute
counts are reported as number of cells per μL of blood.
Humoral immunity
All animals that survived for at least 21 days after chal-
lenge were included in the serological analyses; animals
that were euthanized at earlier time points were not
included.
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Serum neutralization test (SNT)
FMDV-neutralizing antibody titers were determined for
serum samples taken at − 14 and − 7 dpi (vaccinated
animals only; 0 and 7 dpv, respectively), and at 0, 7, 14,
21, 28, and 35 dpi for all animals. Sera were heat inacti-
vated for 30 min at 56 °C and used in a microtiter
neutralization assay. Serial fourfold dilutions of serum
(in MEM with 25 mM HEPES) on 96-well plates (from
an initial dilution of 1/8 down to 1/32768) were incubated
with 100 50 % tissue culture infective doses (TCID50) of
FMDV A24 Cruzeiro for 1 h at 37 °C and 5 % CO2.
Freshly trypsinized LFBK-αVβ6 cells [62, 63] were resus-
pended in MEM with 25 mM HEPES, 4 × 104 cells/well
were added to the plates, and the plates were incubated
for another 72 h at 37 °C and 5 % CO2. After microscopic
evaluation of cell monolayers, the plates were treated with
crystal violet dissolved in tissue fixative (HistoChoice®;
AMRESCO, Solon, OH, USA), then washed and air-dried
before cytopathic effect was again evaluated visually.
Titers were calculated as the reciprocal of the highest
dilution of serum that fully neutralized the virus in
50 % of replicate wells.
FMDV-specific antibody ELISAs
Serum samples were collected on days − 14, −10, −7
(vaccinated animals only), 0 to 10, 14, and 21 after chal-
lenge infection and were used without prior heat inacti-
vation. An indirect double antibody sandwich ELISA
was developed for the detection of FMDV-specific IgM
and IgG in serum. Optimal concentrations of reagents
were determined by checkerboard titration. Each re-
agent was added at a volume of 100 μl per well, except
where indicated. All incubations were at 37 °C for an
hour, shaking, except where indicated. All washes were
performed four times with PBST, 300 μl per well. All
dilutions were performed in blocking buffer (BB, 10 %
normal horse serum in PBST) except where indicated.
Immulon 2HB plates (Thermo Scientific) were coated
with anti-FMDV-A polyclonal rabbit serum (Pirbright
Institute, Pirbright, United Kingdom) at a dilution of
1/1000 in fresh carbonate/bicarbonate buffer (0.05 M,
pH 9.6, Sigma-Aldrich) by incubation overnight at 4 °C.
After washing, plates were incubated with 200 μl per well
of BB. After emptying plates, they were incubated with
positive and negative (made by BEI inactivation of mock-
and virus-infected cells) antigen preparations that were
added to negative and positive columns, respectively. After
washing, serum samples were added at a dilution of 1/100
for IgM detection, 100 μL each on negative- and positive-
antigen coated wells. The same was true for IgG detection,
but at a dilution of 1/500. In each plate, standard positive
and negative sera were included. The standard negative
serum was obtained from animals that were FMDV-
antibody free. Standard positive sera were chosen during
the initial phase of the development of the assays be-
cause of their high titer and high maximum absorbance
value. After incubation and washing, the bound bovine
antibodies were detected using sheep anti-bovine IgM
or sheep anti-bovine IgG heavy chain directly conju-
gated to horseradish peroxidase (A10-101P or A10-
118P, respectively; Bethyl Laboratories, Inc., Montgomery,
Texas). After incubation and washing, ELISA was com-
pleted by addition of substrate solution (SureBlue per-
oxidase substrate, Kirkegaard & Perry Laboratories [KPL],
Gaithersburg, MD, USA) and stopped after 10 min at
room temperature by addition of 50 μl/well of stop solu-
tion (BlueStop; KPL). Absorbance was measured with an
ELx808 microplate reader (BioTek, Winooski, VT, USA)
using a 630-nm filter. For each sample, a net OD was
calculated by subtracting the reading of the negative-
antigen well from the positive-antigen well. For each plate,
the net ODs of test samples were then divided by the net
OD of the positive control sample on the same plate.
Identical aliquots of the same positive control were used
for all plates, and results are reported as fractions of the
net OD of the positive control (nFPC). To further correct
for non-specific reactivity, the nFPC value of the sample
taken on the day of first exposure to FMDV (either vac-
cination or challenge) was subtracted from the nFPC
values of all subsequent samples of the same animal.
FMDV-specific B-cell ELISPOT
FMDV-specific antibody-secreting-cell counts from six
non-vaccinated animals that survived until 35 dpi were
obtained by ELISPOT. Filter plates (EMD Millipore)
were coated with monoclonal antibodies against bovine
IgM (IL-A30; 1/1000), IgG1 (IL-A60; 1/500) or IgG2
(IL-A74; 1/25) (International Livestock Research Institute,
Nairobi, Kenya) diluted in fresh carbonate/bicarbonate
buffer (0.05 M, pH 9.6, Sigma-Aldrich), incubated over-
night at 4 °C, and washed and blocked with ELISPOT
media (supplemented RPMI-1640 with 12 % horse serum).
Fresh PBMCs were serially diluted in ELISPOT media,
and 5 × 105, 2.5 × 105 and 1.25 × 105 cells from each
sample were seeded in duplicate wells on the same
plate, together with a media-only control. After over-
night incubation at 37 °C with 5 % CO2 and thorough
washing with PBS with 0.1 % polysorbate (TWEEN®) 20
(PBST) in an automated plate washer, biotinylated FMDV
A24 Cruzeiro antigen (1/500 in PBST) was added to the
plates. After a 1-h incubation at room temperature and
further washing, HRP-conjugated neutravidin was added
at a dilution of 1/1000 (in PBST), and the plates were in-
cubated for 1 h at room temperature and washed again.
Captured FMDV antigen was visualized with TrueBlue
peroxidase substrate (KPL) and spots were counted with
an ImmunoSpot Analyzer (Cellular Technology Limited,
Shaker Heights, OH, USA). Spot counts were normalized
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to the total input of PBMCs, and the IgM count as well
as the combined IgG1 and IgG2 counts were used for
comparison with the FMDV antibody ELISA results.
Statistical analysis of hematology and flow cytometry
data
For data analysis, animals were grouped by vaccination
or persistence status. Twenty-four animals remained for
at least 3 weeks after challenge and were classified as
FMDV carriers or non-carriers based on virus isolation
results from TTE-treated probang samples. Data were
graphed and analyzed with Excel (Microsoft, Redmond,
WA, USA) and the R statistical environment [64], par-
ticularly the ggplot2 package [65]. Group means are
generally annotated with their 95 % confidence intervals
(CI95) to facilitate visual comparisons between groups.
For group sizes of 3 or fewer, or where between-group
comparisons are not meaningful, standard deviations are
shown instead.
The hematology and flow cytometry data were ana-
lyzed in R with linear mixed-effects models as imple-
mented in lme4 [66], using the car, phia, and lsmeans
packages for post-hoc analyses of specific linear combi-
nations of factor levels. Two models were built for each
outcome variable (white blood cells, neutrophils, lym-
phocytes, monocytes for hematology, and CD3+, CD3+
γδTCR−CD4+, CD3+γδTCR−CD8+ for flow cytometry),
one with only vaccination status, time, and their inter-
action term as fixed effects, and another that additionally
included persistence status and all interactions between
the main effects. This dual approach was chosen because
information on persistence status was only available for
half of the animals in the study. Animal ID was included
as a random effect in all models. For flow cytometry out-
come variables, intercepts and slopes were allowed to vary
between animals (random intercept and slope), whereas
hematology models only had random intercepts.
Where an initial ANOVA (Type II Wald chi-square
tests) found significant interactions between status (by
vaccination or persistence) and time after infection, pair-
wise contrasts for the levels of the status factor (vaccin-
ation or persistence) were evaluated for each level of the
time factor – i.e., difference between vaccinated/non-vac-
cinated or persistent/non-persistent for each day. Changes
in an outcome variable over time were evaluated with cus-
tom contrasts (e.g., dpi1 - dpi0) for each level of a status
factor; similarly, the effect of time alone was evaluated by
averaging across both levels of the status factor and apply-
ing the custom contrasts. P-values from linear hypothesis
tests on the models are reported approximately; any
p-value <0.05 was considered significant.
For the association between viremia and type I/III
IFN activity in serum, the test statistic was calculated
using Pearson’s product moment correlation coefficient.
The asymptotic 95 % confidence interval is based on
Fisher’s Z transform.
The difference between absolute CD4+ and CD8+ αβ
T cell counts in non-vaccinated animals before and
after challenge (0 vs. 5 dpi) was evaluated with a paired
t-test. The variance was estimated separately for both
groups and the Satterthwaite approximation to the de-




The overarching goal of this work was to investigate
systemic trends associated with 2 categorical factors:
vaccination status at the start of the experiment and
FMDV carrier status determined at the end of the
study. Animals are defined and stratified as “carrier”,
“non-carrier”, or “undetermined” for the entire study
based on their final status at the end of the experiment
(Fig. 1).
The OIE defines FMDV carriers as animals in which
the virus persists for more than 28 days after infection
[6]. In the present study, however, all probang samples
from non-carriers were virus-negative by 21 dpi and
remained negative, whereas all animals that were virus-
positive in their 21-dpi probangs remained virus-positive
until 28 dpi and beyond; there was no change in viral
shedding in probangs in any animal between 21 dpi and
the end of the experiment. Thus, for the purposes of this
study, FMDV persistence was defined by sustained de-
tection of infectious FMDV in probang samples until at
least 21 dpi, or until the day of necropsy, whichever was
later. Using this definition, 8 out of 13 non-vaccinated
animals (61.5 %) which had survived until or past 21 dpi
were determined to be persistently infected carriers,
whereas 5 out of 13 non-vaccinated animals (38.5 %)
had successfully cleared the infection. Of 11 vaccinated
animals, 6 were carriers (54.5 %) and 5 non-carriers
(45.5 %). Animals that were euthanized before 21 dpi
were assigned an “undetermined” persistence status.
The vaccinated non-carrier group was further segre-
gated into two distinct categories based on the observa-
tion that three animals lacked convincing virological
evidence of infection. All vaccinated non-carrier animals
were similar in that there was no detectable viral RNA
or infectious virus in OPF, nor was any infectious virus
found in tissue samples taken at necropsy. However, two
out of the five vaccinated non-carriers had FMDV RNA
in nasopharyngeal tissues at 21 or 35 dpi, indicating
previous infection, while the other three did not [12].
Additionally, the three tissue-RNA-negative cattle did
not seroconvert against FMDV non-structural proteins,
while all other vaccinated and non-vaccinated non-carriers
did (not shown). Taken together, this was considered an
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indication of possible sterile protection, and on this
basis, the animals were treated separately and not in-
cluded with the other non-carriers except for the total
count. Specifically, these animals were included in all
analyses that stratify animals by vaccination status but
were excluded from all analyses that stratify animals by
persistence status.
Clinical disease, viremia, and type I/III IFN response
All non-vaccinated steers developed moderate to severe
clinical FMD after virus exposure (Fig. 2a). Characteris-
tic lesions were seen in and around the mouth, including
vesicles on the tongue and dental pad as well as on the
skin around nostrils and lips. Foot lesions, including ves-
icles in the interdigital clefts and on coronary bands
were often accompanied by moderate lameness. Vesicu-
lar lesions first appeared between 2 and 6 dpi (generally
on the first day after the onset of detectable viremia)
and resolved within approximately 10 days. None of the
vaccinated steers developed clinical FMD after challenge
(Fig. 2b).
Viremia (defined by presence of viral RNA in serum)
was detected in all non-vaccinated steers after virus
challenge. The earliest detection of FMDV RNA oc-
curred between 1 and 5 dpi (mean time to initial detec-
tion: 3 days), with levels again declining below assay
detection limits after four to six days of detection. The
peak of mean viremia (6.7 log10 FMDV GCN/mL) across
all non-vaccinated animals occurred on 5 dpi. Viremia
and type I/III IFN activity in serum were significantly
correlated (r = 0.53 [0.37; 0.66], p < 0.01), and peak viremia
coincided with peak type I/III IFN activity (Fig. 2a). No
difference was seen in clinical disease, the magnitude of
the IFN response, or the level of viremia between the
groups of animals that subsequently diverged into carriers
and non-carriers. FMDV RNA was not detected in sera of
any of the vaccinated steers at any time, and there was
no detectable type I/III IFN activity in the serum of
Fig. 2 Lymphopenia during acute FMDV infection. a/b non-vaccinated animals, c/d vaccinated animals. Mean lymphocyte counts (black squares),
viral load (red circles), and type I/III IFN response (gold diamonds) in peripheral blood (b/d), as well as rectal temperature (purple crosses) and
cumulative clinical score (blue triangles) (a/c) are shown with 95 % confidence intervals. The group means for non-vaccinated animals were
calculated after individual timescales had been adjusted so that the onset of viremia coincided for all animals (0: first day of viremia). Asterisks
mark days on which mean lymphocyte counts were significantly different from the initial value in the fitted model. The limit of detection for
the FMDV real-time RT-PCR is 1.6 log10 FMDV GCN/mL
Eschbaumer et al. BMC Veterinary Research  (2016) 12:205 Page 8 of 18
vaccinated animals after challenge (Fig. 2b). The Mx/
CAT assay does not distinguish between type I and type
III interferon [20]; hence it was not determined whether
the observed interferon response was mediated by type I
or type III interferon or both.
Hematology: vaccinated vs. non-vaccinated animals
No hematological changes were observed after vaccination,
and the two groups (vaccinated and non-vaccinated) did
not differ in any cell population in the complete blood
count prior to challenge (Fig. 3). All further comparisons
are made relative to the day of challenge. After challenge,
the mean total WBC count decreased in non-vaccinated
animals, while it increased in vaccinated animals. Neither
change was significant within the groups, but the difference
between non-vaccinated animals and vaccinated animals
was significant between 4 and 10 dpi (p <0.05) (Fig. 3a).
Lymphocyte counts diverged starting at 4 dpi, with vac-
cinated steers having significantly higher counts than
non-vaccinated steers (p <0.05) (Fig. 3c). This separ-
ation was maintained throughout the early phase of the
experiment (until 9 dpi). Within the vaccinated popula-
tion, mean lymphocyte counts were significantly in-
creased over pre-challenge levels (0 dpi) on 4 and 5 dpi
and again from 7 to 9 dpi (p <0.05). Lymphocyte counts
were significantly decreased in non-vaccinated animals
from 4 to 8 and on 10 dpi (Fig. 3c). The decrease in cir-
culating lymphocytes closely followed the increase in
viremia and type I/III IFN activity in serum detected in
this group (Fig. 2). All group means were within established
reference ranges for cattle; thus, the changes in lympho-
cyte quantities are indicative of relative lymphocytosis (in
Fig. 3 White blood cell subpopulations in vaccinated and non-vaccinated steers. a Total WBC count. b Neutrophils. c Lymphocytes. d Monocytes.
Animals were assigned to groups based on their FMDV vaccination status, without regard to their persistence status. Vaccinated animals have
blue lines and squares, and non-vaccinated animals have red lines and circles. The plots show the group means with 95 % confidence intervals.
The upper part of panel a shows the number of animals (n) that contributed data for each time point; this number is the same for all panels. All
47 animals contribute data to the 0-dpi group means; as animals are being euthanized beginning on 1 dpi, the size of each group decreases
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vaccinated animals) and relative lymphopenia (in non-
vaccinated animals) after challenge.
Similar to the mean lymphocyte counts, mean mono-
cyte counts varied by vaccination status and time after
infection. Mean monocyte counts in non-vaccinated
steers were not significantly different over the course of
the experiment. Vaccinated steers, however, had relative
monocytosis from 5 to 9 dpi (p <0.05) (Fig. 3d). Six indi-
vidual animals exceeded the threshold for absolute
monocytosis at least once, but the group means did not.
The three vaccinated animals (out of 18) that lacked
definitive evidence of local virus replication did not
have increased monocyte counts (not shown).
Mean neutrophil counts did not differ significantly be-
tween vaccinated and non-vaccinated steers, nor did they
vary significantly over the course of infection (Fig. 3b).
Hematology: FMDV carriers vs. non-carriers
FMDV persistence status did not correlate with differences
in total WBC count or any of its subpopulations. Carrier
and non-carrier steers had similar mean hematological pa-
rameters over the course of infection (Fig. 4). Non-carrier
steers had slightly higher mean lymphocyte counts from 3
to 10 dpi, but there was no statistically significant differ-
ence (p > 0.05). Overall, the observed hematological differ-
ences were more substantively associated with vaccination
status than with persistence status.
In Fig. 3, animals are assigned to groups based on their
FMDV vaccination status, without regard to their persist-
ence status, whereas in Fig. 4, they are assigned to groups
based on their FMDV persistence status, without regard
to their vaccination status. A set of charts showing the
hematology data stratified by vaccination and persistence
Fig. 4 White blood cell subpopulations in carriers and non-carriers. a Total WBC count. b Neutrophils. c Lymphocytes. d Monocytes. Animals were
assigned to groups based on their FMDV persistence status, without regard to their vaccination status. Persistently infected FMDV carrier animals
have orange lines and squares, and non-carriers have green lines and circles. The plots show the group means with 95 % confidence intervals. The
upper part of panel a shows the number of animals (n) that contributed data for each time point; this number is consistent for all panels. The
number of animals contributing data to each time point is stable between 0 and 21 dpi
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status at the same time is included as Additional file 1:
Figure S1 in the online version of this article.
Flow cytometry: Vaccinated vs. non-vaccinated animals
Serial examinations of phenotypic characteristics of PBMCs
from forty-seven steers were performed on up to 22 sam-
ples per animal by staining in duplicate and evaluating by
flow cytometry. The mean coefficent of variation between
replicates of the same sample was less than 3 %.
The relative size of the CD3+ population within the mor-
phological lymphocyte gate (forward and side scatter) was
variable over time, and trended lower in non-vaccinated
animals after challenge. There was a significant difference
between vaccinated and non-vaccinated animals on 4 and
5 dpi (p <0.05; not shown).
Based on relative percentage-of-parent values, the CD4+
and CD8+ αβ T cell subpopulations in vaccinated animals
did not change significantly after challenge, but there was
a significant increase of CD4+ αβ T cells and a corre-
sponding decrease of CD8+ αβ T cells in non-vaccinated
animals from 3 to 6 dpi (compared to day 0; p <0.05 for
all 4 days, Fig. 5a, b). For each subpopulation, the differ-
ence between vaccinated and non-vaccinated animals was
significant for the same time period (3 to 6 dpi, p <0.05).
The CD4+/CD8+ ratio in non-vaccinated animals transi-
ently increased from 3.2 at the day of challenge to 4.0 on
5 dpi, while it slightly decreased (from 3.3 to 3.1) in vacci-
nated animals.
In order to translate relative population measures
obtained by flow cytometry to absolute counts, the
percentage-of-parent values from the flow cytometry ana-
lysis were applied to the lymphocyte counts obtained with
the hematology analyzer. When this conversion was per-
formed, the increase in total circulating lymphocytes (com-
pared to the day of challenge) of up to 25 % in vaccinated
animals (Fig. 3c) had greater influence than the relative dif-
ferences between vaccinated and non-vaccinated animals
that have been described above. Thus, absolute quantities
of both CD4+ as well as CD8+ αβ T cells were significantly
higher in PBMCs of vaccinated steers than in non-
vaccinated steers (p <0.05) from 2 to 10 dpi (Fig. 5c, d).
The absolute decrease (compared to the day of chal-
lenge) of the total lymphocyte count in non-vaccinated
animals also influenced the counts of the CD4+ and CD8+
αβ T cell subpopulations. In relative terms, CD4+ αβ T
cells had been transiently increased in non-vaccinated
Fig. 5 CD4+ and CD8+ αβ T cells in vaccinated and non-vaccinated animals. Panels a and b show percentage values relative to the CD3+ αβ T
cell parent population, and panels C and D show absolute cell counts per μL of blood obtained by a dual-platform method. Group means (CD4+:
diamonds, CD8+: triangles) are annotated with their 95 % confidence intervals, non-vaccinated animals are shown in red and vaccinated animals
in blue. Based on relative percentage-of-parent values, there was a significant increase of CD4+ αβ T cells (panel a) and a corresponding decrease
of CD8+ αβ T cells (b) in non-vaccinated animals. Translated to absolute counts, the increase in total circulating lymphocytes of up to 25 % in
vaccinated animals had greater influence than the relative differences between vaccinated and non-vaccinated animals. Thus, absolute quantities
of both CD4+ (c) as well as CD8+ αβ T cells (d) were significantly higher in PBMCs of vaccinated steers than in non-vaccinated steers
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animals, while CD8+ αβ T cells had shown a complemen-
tary decrease (Fig. 5a, b). The relative increase in CD4+
cells partially counteracted the total decrease in lympho-
cytes, whereas the decrease in CD8+ cells became more
pronounced once absolute counts were taken into account
(Fig. 5c, d). Absolute CD4+ cell counts during acute infec-
tion fluctuated substantially more than CD8+ counts
(Fig. 5c, d). On day 5 after infection, the day with the
largest CD4+/CD8+ ratio (4.0, see above) as well as the
nadir of the lymphocyte count in non-vaccinated ani-
mals (Fig. 3c), the absolute CD8+ cell count in non-
vaccinated animals was reduced by approximately 20 %
compared to day 0 (166 ± 34 vs. 202 ± 30 per μL of
blood; means and CI95, p = 0.03), while the absolute
CD4+ count was similar to the initial level (624 ± 85 vs.
619 ± 66, p = 0.91).
Flow cytometry: FMDV carriers vs. non-carriers
There were no significant differences between carrier
and non-carrier animals in the kinetics of any T cell
population investigated herein, independent of whether
vaccinated and non-vaccinated animals were analyzed
together or separately, and independent of the measure-
ment scale (relative or absolute).
FMDV-specific humoral immune response
In vaccinated animals, no FMDV-specific antibodies were
detected at 4 dpv (by ELISA only; the 4-dpv sample was
not tested in the SNT), but all vaccinated animals had
developed FMDV-specific IgM and IgG by 7 dpv, and
most had detectable neutralizing antibody at the day of
challenge (14 dpv; Fig. 6).
All vaccinated animals had detectable FMDV-specific
IgM on the day of challenge. Vaccinated animals that
went on to become FMDV carriers maintained their pre-
challenge FMDV IgM levels for the duration of the study,
whereas FMDV-specific IgM in vaccinated animals that
did not become persistently infected was markedly re-
duced by 7 dpi (see boxes in Fig. 6a, b). In contrast,
FMDV-specific IgM in serum from non-vaccinated ani-
mals was first detected on day 5 after challenge. Levels
increased quickly over the next few days and peaked on
9 dpi. In carriers and non-carriers IgM then declined
steadily until the end of the experiment, but remained
detectable throughout.
Fig. 6 Serological response to FMDV vaccination and challenge. Animals are grouped by vaccination status (“vaccinated”, “not vaccinated”) and
FMDV persistence status (“carrier”, “non-carrier”, or “no evidence of infection” for vaccinated non-carriers without virological evidence of FMDV
replication after challenge). Each panel shows group means with standard deviation for one combination of the two categories. In all five panels,
purple lines with square markers show FMDV-specific IgM levels, golden lines with round markers show FMDV-specific IgG and maroon lines with
diamond markers show FMDV A24 neutralization titers. The gray boxes highlight the potentially different post-challenge IgM kinetics in vaccinated
carriers and non-carriers (see text). PC = positive control
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After the first detection on 7 dpv, FMDV-specific IgG
in vaccinated animals increased steadily until 14 dpi. All
vaccinated animals had detectable FMDV-specific IgG
on the day of challenge. In non-vaccinated animals, spe-
cific IgG was first detectable on 6 dpi and rose quickly
until 14 dpi. After 14 dpi, the levels of specific IgG
remained stable in vaccinated and non-vaccinated ani-
mals, but the final levels in vaccinated animals were
higher than in non-vaccinated animals (Fig. 6a, b).
Neutralizing antibody levels in vaccinated and non-
vaccinated animals generally correlated with FMDV-
specific IgG rather than with IgM. However, in contrast
to the ELISA data, final levels of neutralizing antibodies
were higher in animals that had not been vaccinated be-
fore challenge and thus had developed fulminant FMD
(Fig. 6d, e). The three vaccinated animals without viro-
logical evidence of local FMDV replication or dissemination
had lower specific antibody levels than other vaccinated
animals, both before and after challenge (Fig. 6c); how-
ever they did have increases in IgG and neutralization
titers after challenge.
Apart from the slightly different IgM kinetics in vacci-
nated animals after challenge, there was no difference in
FMDV-specific circulating antibody between carriers and
non-carriers.
Isotype-specific characterization of anti-FMDV B cells
FMDV-specific circulating B cells of six non-vaccinated
animals were evaluated using an antibody ELISPOT assay.
Anti-FMDV antibody-secreting cells were first detected in
non-vaccinated animals on 5 dpi. IgM-secreting cells
peaked between 7 and 14 dpi, and had disappeared from
peripheral blood by 14 dpi. IgG-secreting cell counts in cir-
culation increased until 14 dpi, and then declined. Low
levels of FMDV IgG-secreting cells remained detectable in
peripheral blood until the end of the experiment (Fig. 7).
Discussion
The present study examined the systemic response to
FMDV infection in cohorts of non-vaccinated and vacci-
nated cattle with the purpose of investigating systemic
immune system factors that may correlate with the
divergence between FMDV carriers and non-carriers.
Persistent infection can follow either a clinical or a sub-
clinical FMDV infection and generally occurs at the
same rate regardless of vaccination reviewed in [67].
The protective efficacy of Ad5-FMDV vaccination against
disseminated disease has been demonstrated previously
[46, 68, 69], but the incidence and characteristics of per-
sistent infection after challenge of Ad5-FMDV-vaccinated
cattle was studied here for the first time. Complete blood
counts, T lymphocyte subpopulations, type I/III IFN re-
sponse, as well as FMDV-specific antibody production
and activity were compared between vaccinated and non-
vaccinated animals and between carriers and non-carriers
at an unprecedented level of detail. Before challenge, vac-
cinated cattle had detectable humoral immunity against
FMDV. After challenge, all non-vaccinated steers became
viremic and developed clinical disease, while the vacci-
nated steers did not. This divergence coincided with dis-
tinctive differences in several parameters. On the other
hand, only slight differences were identified between ani-
mals that went on to become FMDV carriers compared to
those which cleared the infection.
The present study confirmed earlier findings that sum-
mary WBC levels in non-vaccinated animals remain
within the clinical reference range during acute FMDV in-
fection and do not change significantly from the outset
[28]. There was, however, a significant change in lympho-
cyte levels, which transiently decreased in non-vaccinated
animals after FMDV challenge. This relative lymphopenia
was significant compared to pre-infection levels; however,
the animals were never lymphopenic relative to the estab-
lished clinical reference range [56], which underscores the
utility of reference change values over population-level
standards in animal research [70].
Lymphopenia is a common feature of acute viral infec-
tions [71]. It is a well-described phenomenon in FMDV-
infected pigs [24, 25, 72], and has previously been re-
ported in FMDV-infected cattle in at least two studies
[20, 26]. There are several mechanisms by which viruses
can cause lymphopenia. Lymphocytes may be redistribu-
ted from the blood into infected tissues, e.g. through the
action of type I IFNs. Alternatively, apoptosis of lympho-
cytes can be a direct result of viral infection or caused
indirectly through cytokine induction [73]. In the present
study, the decrease in circulating lymphocytes closely
followed the increase in systemic type I/III IFN activity,
which in turn was highly correlated with FMDV viremia.
Thus, these findings are consistent with the observed lym-
phopenia being due to IFN-induced lymphocyte migration
Fig. 7 FMDV-specific humoral immune response in 6 non-vaccinated
animals. Antibody-secreting cells (ASC) in peripheral blood were
counted with ELISPOT assays, and circulating antibody was measured
by sandwich ELISAs. IgM is shown in purple, IgG in gold. Error bars
show sample standard deviation. PC = positive control
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from the blood to sites of infection or lymphoid tissues
[74]. The CBC only examines circulating cells; animals
with a relative lymphopenia may have normal or even in-
creased levels of total body lymphocytes and the reduction
in circulating lymphocytes alone does not necessarily
represent a decline in immune competence. It has been
argued that transient virus-induced and IFN-mediated
lymphopenia is, in fact, a physiological response and
beneficial to the host reviewed in [74].
Similarly, increased lymphocyte counts, as were de-
tected in the vaccinated animals in the present study,
are often seen after antigenic stimulation [71]. The recall
response after challenge of vaccinated animals is the result
of an increased quantity of primed antigen-specific B and
T cells, which can expand more quickly. Memory cells are
activated more readily than naïve cells and can respond to
lower doses of antigen [75].
As the bridge between innate and adaptive immunity,
monocytes and macrophages are a key component in
antigen presentation, phagocytosis, and viral clearance
[76]. They usually form only a small part of the circulating
leukocyte pool. In the present study, monocyte numbers
did not change significantly after vaccination, or after
FMDV infection of non-vaccinated animals, but there
was a striking pattern in vaccinated steers after challenge.
Four days after challenge, and two days after circulating
lymphocyte counts had started to increase, monocyte
counts rose sharply and remained high (approximately
50 % above baseline) for several days. Sigal et al. [77] have
previously reported a similar increase of monocytes in
FMDV-vaccinated animals 1 week after challenge.
Monocytes are released into circulation from the bone
marrow and spleen in response to inflammation signals
[78], and move quickly to sites of infection where they dif-
ferentiate into macrophages or dendritic cells. Increased
antigen presentation and lymphocyte activation stimulate
additional monocyte recruitment through positive feed-
back loops [79]. Opsonization by specific antibody and
phagocytosis are major factors in the immune defense
against FMDV [80, 81]. Additionally, pDC activation by
FMDV is also substantially enhanced in the presence of
FMDV-specific antibodies [82]. In the vaccinated animals,
protection from FMD occurred in the presence of abun-
dant anti-FMDV immunoglobulin combined with elevated
circulating monocyte counts, both of which were likely
contributors to the effective immune response.
It has previously been shown that there is a strong sys-
temic type I/III IFN response during acute FMDV infec-
tion of cattle [19, 21, 22], and this was again confirmed
in the large cohort of unvaccinated cattle in the present
study. High IFN activity is also detectable in tissues of
FMDV-infected animals, but it is restricted to sites of
virus replication [22]. It is unclear how much of the
locally produced IFN enters the vasculature, and it has
been suggested that the circulating type I/III IFN is in-
stead produced by CD4+ pDCs interacting with immune-
complexed virus [18]. A flow cytometric analysis of ex vivo
interferon production in pDCs from the FMDV-infected
animals would have provided useful information in this
regard, but this was beyond the scope of the present
study.
No infectious virus or FMDV RNA was detected in
serum of vaccinated animals in the present study; thus,
the lack of a systemic type I/III IFN response could be
explained by the absence of the crucial stimulus for its
production. However, induction of transcription of IFN
genes and IFN bioactivity was detected in pharyngeal
tissues of vaccinated cattle from this study [38].
In addition to its critical role in innate immunity, type
I IFN can act directly on both CD4+ and CD8+ T cells,
positively or negatively influencing their function reviewed
in [83]. T cells are the dominant lymphocyte population in
peripheral blood of cattle [84]. For the first time, the
present study identified significant changes in αβ T cells in
non-vaccinated steers challenged with FMDV, comple-
menting earlier work on γδ T cells [85]. After infection,
non-vaccinated animals had a significant decrease in the
relative quantity of CD8+ αβ T cells for several days, while
the same cell population in vaccinated animals remained
stable. Conversely, the relative CD4+ αβ T cell population
in non-vaccinated animals was larger during that time,
but did not change in vaccinated animals. In order to de-
termine which subset was responsible for the change in
the CD4+/CD8+ ratio, lymphocyte counts from the CBC
were applied to the relative changes of lymphocyte sub-
populations – commonly referred to as the dual-platform
method of obtaining absolute counts [60]. The multicolor
staining panel used in the present study also accounts for
non-T lymphocytes and γδ T cells. Using this method, ab-
solute CD4+ counts in non-vaccinated animals were found
to be stable during acute infection, while the absolute
CD8+ counts were significantly decreased. This indicates
selective depletion (or redistribution) of circulating CD8+
αβ T lymphocytes in FMDV-infected non-vaccinated cat-
tle. A similar pattern has been previously described in
swine [24, 25], compounded by evidence of functional im-
pairment (e.g., mitogen unresponsiveness) of the residual
circulating T cell population. A variety of explanations for
these observations have been suggested [74], including
FMDV infection of T lymphocytes or T-cell suppression
by IL-10 overproduction [86]. Joshi et al. [87] reported a
similarly inhibited response to mitogen in FMDV-infected
bovine lymphocytes, but other studies found no evidence
of changes in CD4+ and CD8+ populations, T-cell impair-
ment or increased circulating IL-10 during acute FMDV
infection in small cohorts of cattle [27, 28].
The time course of the FMDV-specific antibody response
observed in the present study was similar to previously
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published results from other groups [27, 88–90]. Direct
comparisons of the magnitude of the response, however,
are impossible because of differences in the test format
(endpoint dilution vs. optical density at a fixed dilution, use
of monoclonal anti-isotype vs. polyclonal anti-isotype anti-
bodies, etc.). In addition, neither system allows for a fully
quantitative comparison of different immunoglobulin iso-
types within a sample, only of relative levels of the same
isotype between samples [89].
When comparing the antibody development after chal-
lenge between FMDV-vaccinated and non-vaccinated
animals, Mulcahy et al. [89] saw a transient increase of
specific IgM in non-vaccinated animals, followed by a
sustained increase of specific IgG. This is the classical
pattern of a primary immune response [91] that was also
seen in non-vaccinated animals in the present study.
Similar to what has been discussed for cellular adaptive
responses, secondary or recall antibody responses differ
from primary responses. They occur more rapidly, they
consist of relatively more IgG than IgM, and they are of
higher affinity [75]. Indeed, no rise in specific IgM was
seen after challenge in the vaccinated animals in the
present study, but FMDV-specific IgG levels in vacci-
nated animals did increase after challenge.
This increase was also seen in the three vaccinated ani-
mals that lacked evidence of local virus replication, pos-
sibly because antibody-bound FMDV was recognized by
the immune system and induced an anamnestic response.
Alternatively, there could have been low-level replication
that was not directly detectable and which was insufficient
to induce measurable antibodies against non-structural
proteins. Overall, the data support these animals not hav-
ing been infected. Strikingly, they only had low neutraliz-
ing antibody titers and no detectable type I/III interferon
in serum before challenge; thus, the specific mechanisms
that facilitated their apparent sterile protection remains
undetermined. While the neutralizing antibody profiles
between serum and nasal fluid of FMDV-vaccinated pigs
are similar, this is not necessarily true for cattle [92], and
the low serum titers are not indicative of a similarly low
mucosal response.
Persisting serum IgM is used to diagnose chronic viral
infections such as hepatitis B and C in humans. Contrary
to the results presented here, Salt et al. [90] had not seen
such a pattern for FMDV-specific IgM in carriers. In the
present study, modestly elevated FMDV-specific IgM
was detected in carriers. This may be because persistent
FMDV infection is not highly productive, unlike the afore-
mentioned chronic infections. It is interesting to note, too,
that while IgM remains detectable, IgM-secreting cells
disappear from circulation, possibly indicating a more lo-
calized production of the antibodies-similar to what has
been described for the IgA response to persistent infection
[42]. The magnitude of the difference in IgM kinetics
between carriers and non-carriers, however, appears to be
too small to be of diagnostic utility. As has been reported
previously reviewed in [4], no component of the serum
antibody response in the present study was significantly
different between carriers and non-carriers.
Conclusions
This study corroborates the notion that vaccination and
prevention of clinical disease offer no protection against
either primary or persistent FMDV infection [12, 38, 90].
This is the first use of high-resolution hematology and
multi-color flow cytometry data from a large cohort of
animals, all exposed to the virus under simulated-natural
conditions and closely monitored for the full course of in-
fection. Lymphopenia and selective CTL depletion were
found to be significant phenomena during the acute infec-
tion of naïve cattle, in contrast with a robust cellular
immune response in vaccinated animals. However, none
of the systemic parameters examined–type I/III interferon,
FMDV-specific antibodies, circulating leukocyte popula-
tions and T-lymphocyte subsets–were associated with the
FMDV carrier state divergence, emphasizing the highly
localized nature of persistent FMDV infection. This sug-
gests that tissue-level studies of sites of persistence may be
required to elucidate the mechanisms associated with es-
tablishment and resolution of persistent FMD, and such
studies are currently underway in our laboratory.
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Additional file 1: Figure S1. White blood cell subpopulations by
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means are shown with 95 % confidence intervals. Means are marked
with orange circles for carrier animals and green circles for non-carriers;
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